Brivaracetam for the treatment of epilepsy (Q38694479)

5 September 2017

title

Brivaracetam for the treatment of epilepsy (English)

1 reference

5 September 2017

1 reference

ChEBI release 2020-05-28

Pavel Klein

1 reference

5 September 2017

Ivana Tyrlikova

series ordinal

1 reference

5 September 2017

Milan Brazdil

series ordinal

1 reference

5 September 2017

Ivan Rektor

series ordinal

1 reference

5 September 2017

language of work or name

English

0 references

publication date

13 January 2016

1 reference

Expert Opinion on Pharmacotherapy

5 September 2017

published in

1 reference

5 September 2017

1 reference

5 September 2017

1 reference

5 September 2017

page(s)

283-295

1 reference

Estimation of the burden of active and life-time epilepsy: a meta-analytic approach

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

Patterns of treatment response in newly diagnosed epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

Early identification of refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

Modern antiepileptic drug development has failed to deliver: Ways out of the current dilemma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

Brivaracetam: a rational drug discovery success story

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

Brivaracetam does not alter spatial learning and memory in both normal and amygdala-kindled rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

Brivaracetam disposition in mild to severe hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

Effect of brivaracetam on cardiac repolarisation--a thorough QT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1135129

10.1517/14656566.2016.1135129

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference